Disease · MONDO_0005855
Comparisons in its trials38
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 38
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 8 | 87 of 444 | 52 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: A Lesion Count of 0 or 1 of All Treatable MC at Week 12 | 193 of 444 | 110 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: 90% Reduction From Baseline in the Number of All Treatable MC at Week 12 | 191 of 444 | 107 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12 | 144 of 444 | 88 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: deaths from any cause | 0 of 444 | 0 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: serious adverse events | 0 of 444 | 1 of 447 | 891 | NCT04535531 | Trial comparisons |
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 8 | 33 of 237 | 7 of 118 | 355 | NCT03927703 | Trial comparisons |
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12 | 71 of 237 | 24 of 118 | 355 | NCT03927703 | Trial comparisons |
| SB206 12% vs Placebo Comparator: deaths from any cause | 0 of 237 | 0 of 117 | 354 | NCT03927703 | Trial comparisons |
| SB206 12% vs Placebo Comparator: serious adverse events | 1 of 237 | 1 of 117 | 354 | NCT03927703 | Trial comparisons |
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 8 | 36 of 236 | 12 of 116 | 352 | NCT03927716 | Trial comparisons |
| SB206 vs Placebo: Complete Clearance of All Treatable MC at Week 12 | 61 of 236 | 25 of 116 | 352 | NCT03927716 | Trial comparisons |
| SB206 vs Placebo: deaths from any cause | 0 of 235 | 0 of 116 | 351 | NCT03927716 | Trial comparisons |
| SB206 vs Placebo: serious adverse events | 0 of 235 | 0 of 116 | 351 | NCT03927716 | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit | 51 of 160 | 18 of 106 | 266 | NCT03377790 | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. | 99 of 160 | 28 of 106 | 266 | NCT03377790 | Trial comparisons |
| VP-102 vs Placebo: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit | 18 of 160 | 4 of 106 | 266 | NCT03377790 | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) | 74 of 160 | 19 of 106 | 266 | NCT03377790 | Trial comparisons |
| VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit | 33 of 160 | 10 of 106 | 266 | NCT03377790 | Trial comparisons |
| VP-102 vs Placebo: Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject. | 9 of 160 | 13 of 106 | 266 | NCT03377790 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005855/comparisons